Achievement of glycaemic targets with weight loss and without hypoglycaemia in type 2 diabetes with the once‐weekly glucose‐dependent insulinotropic polypeptide and glucagon‐like peptide‐1 receptor agonist tirzepatide: A post hoc analysis of the SURPASS ‐1 to ‐5 studies
Authors' conclusion
Across the SURPASS-1 to -5 clinical trials, more tirzepatide-treated participants with T2D achieved clinically meaningful composite endpoints, which included reaching glycaemic targets with various degrees of weight loss and without hypoglycaemia, than those in the comparator groups.
Study context
- Population
- Participants with T2D in the phase 3 SURPASS-1 to −5 trials5 RCTs
- Comparison
- Tirzepatide vs placebo, semaglutide 1 mg or titrated basal insulin
- Primary endpoint
- Composite endpoints:
- HbA1c <7.0%
- ≤6.5% or <5.7% with weight loss ≥5%
- ≥10% or ≥15% and without hypoglycaemia
- Follow-up
- Week 40/52
Methodological detailsby trial, phase 3
- By trial
- Phase 3
Primary result
As reported in the abstract
HbA1c <7.0% with ≥5% weight loss and without hypoglycaemia
Tirzepatide
43% to 82%
Placebo
4%-5%
Semaglutide 1 mg
51%
Basal insulin
5%
P < 0.001 vs. all comparators
Further findings
| Outcome | P value |
|---|---|
| HbA1c <7.0% with ≥10% or ≥15% weight loss and without hypoglycaemiaTirzepatide vs comparators | P < 0.001 or P < .05 |
- HbA1c <7.0% with ≥10% or ≥15% weight loss and without hypoglycaemia: significantly higher with all tirzepatide doses across trials
Composites with HbA1c ≤6.5% or <5.7%
- Similar results; more tirzepatide-treated participants achieved these endpoints vs comparator groups, including semaglutide
Original publication
Achievement of glycaemic targets with weight loss and without hypoglycaemia in type 2 diabetes with the once‐weekly glucose‐dependent insulinotropic polypeptide and glucagon‐like peptide‐1 receptor agonist tirzepatide: A post hoc analysis of the SURPASS ‐1 to ‐5 studies. Diabetes Obes Metab. Published 27 December 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →